Pure apocrine carcinoma of the breast

Last updated
Pure apocrine carcinoma of the breast
Other namesPure apocrine carcinoma, Pure invasive apocrine carcinoma
Breast apocrine carcinoma.jpg
Fig 1
Specialty Oncology, Surgical oncology

Pure apocrine carcinoma of the breast (PACB) is a rare carcinoma derived from the epithelial cells in the lactiferous ducts of the mammary gland. [1] The mammary gland is an apocrine gland. [2] Its lactiferous ducts have two layers of epithelial cells, a luminal layer which faces the duct's lumen (i.e. passageway) and a basal layer which lies beneath the luminal layer. There are at least four subtypes of epithelial cells in these ducts: luminal progenitor cells and luminal mature cells which reside in the luminal layer and mammary stem cells and basal cells which reside in the basal layer. [3] Examination of the genes expressed in PACB cancer cells indicate that most of these tumors consist of cells derived from luminal cells but a minority of these tumors consist of cells derived from basal cells. [4] [5]

Contents

Invasive apocrine carcinomas of the breast with an appreciable amount of apocrine gland-like tissue was termed apocrine breast tumors for decades when in 1988 d'Amore et al named a subset of these carcinomas in which >90% of its tissue consisted of apocrine gland-like tissue as pure invasive apocrine carcinoma. [6] In 2010, Vranic and colleagues added further to the definition of PACP to establish the criteria currently used for its diagnosis. They defined it as a carcinoma that: a) has a component(s) which invades adjacent tissue; b) consists of >90% apocrine gland-like tissue; c) has at least 10% of its cancer cells that express androgen receptors; and d) lacks cancer cells that express estrogen receptors and progesterone receptors. Many PACB tumors have cancer cells which overexpress the HER2/neu receptor-like protein. [7] The World Health Organization (2019) did not define any of the other invasive apocrine carcinomas as diagnostically distinct entities, [8] but did recognize invasive ductal breast carcinoma in which >90% of its cancer cells were apocrine gland cells as "carcinoma with apocrine differentiation." [9] Non-invasive apocrine carcinoma of the breast, i.e. apocrine ductal carcinoma in situ, is classified as a variant of ductal carcinoma in situ breast tumors. [9] Invasive carcinomas consisting of 10%–90% apocrine tumor tissue have been termed apocrine-like invasive carcinoma; these carcinomas sometime have estrogen receptor-positive [1] and/or progesterone receptor-positive tumor cells. [9] Both of these carcinomas are described in the last section (Other types of apocrine carcinomas) of this article.

As defined by the criteria established by Vranic and colleagues, PACB is a rare carcinoma that accounts for about 1% of all breast cancers, [10] occurs primarily in postmenopausal females, [11] and usually presents as an asymptomatic mass that in many cases has spread to nearby axillary (i.e. armpit) lymph nodes. [12] While earlier studies used only some of these criteria to diagnose PACB, the studies reviewed here used all four of them.

Presentation

Due to its rarity and more recent definition, PACB studies have generally consisted of small numbers of patients. In these studies, most individuals diagnosed with PACB presented with an asymptomatic breast tumor discovered by self-palpation or screening methods such as mammography. The mammographic features of PACB included a spectrum of dense masses with associated microcalcifications; these findings are non-specific and similar to those seen in, e.g. invasive carcinoma of no special type. [12] Uncommonly, PACB tumors caused breast symptoms such as a pulling sensation, skin puckering, pain, nipple discharge, [12] or overt ulceration. [13] In one study, 41 individuals presenting with PACB were females aged 32–75 years (mean: 59 years) with 12 (53.7%) being over 59 years old, 35 (85.4%) being postmenopausal, and 6 (14.6%) being of childbearing age; their tumors widest diameter was 0.47–10.00 centimeters (cm) (average: 2.4 cm); and axillary lymph node metastases on the same side as the tumor were present in 20 (48.8%) cases. [11] A study of 15 individuals found 5 (33%) with lymph node metastases, again on the same side as the tumor. [14] A study of 18 females all of whom had HER2/new-positive PACB tumors reported that they were 44–83 years old (median age: 55.5 years); 14 (77.8%) were postmenopausal; the widest diameter of their tumors ranged from 0.8 to 5 cm (average: 4 cm); and 9 (50%) had axillary lymph node metastases. These metastases were detected in from 1 to 10 lymph nodes on the same side as the tumor although one individual had metastases in the lymph nodes of both axillae and another had simultaneous metastases in infraclavicular, i.e. below the clavicle, lymph nodes. [10] Rarely, individuals with PACB have presented with metastases in more distant tissues [11] such as in the lymph nodes of the mediastinum (i.e. central compartment of the thoracic cavity) [13] or in the deltopectoral lymph nodes, i.e. lymph nodes situated below the clavicle and between the pectoralis major and deltoid muscles. [10] Also rarely, individuals previously treated for PACB have later presented with recurrence of their disease in sites where the tumors were surgically removed, in the nearby skin or chest wall, and/or in more distant tissues such as a bone or the brain. [14]

Pathology

Histopathology

Fig. 2 Breast apocrine carcinoma Breast ApocrineCarcinoma HP2 CTR.jpg
Fig. 2 Breast apocrine carcinoma
Fig. 3 Breast apocrine carcinoma Breast ApocrineCarcinoma LP2 CTR.jpg
Fig. 3 Breast apocrine carcinoma

The microscopic histopathology of PACB tumors prepared with hematoxylin and eosin staining shows that >90% of the tumors consist of apocrine gland-like tissue. The lesions must also show that tumor cells have broken through their ducts of origin to invade adjacent tissue in at least one area. Most of the tumor cells (termed type A cells [15] ) typically appear somewhat more irregular than normal apocrine gland cells. They have abundant eosinophilic (i.e. pink due to the uptake of the eosin dye) cytoplasm which contain numerous granules [11] and large mitochondria. [15] Their nuclei are large, variably sized and shaped, have multiple nucleoli (which are eosinophilic [11] and may be distinctively large in size [14] ), and are surrounded by highly visible nuclear membranes. The cells are arranged into solid sheets, nests, papillae, and/or cords (see Figs. 1 and 2). [11] The tumor cells' cytoplasmic granules test positive when treated with the PAS diastase stain. [16] Binucleated cells, i.e. cells with two nuclei, are common. [10] Less commonly, type B apocrine cells are present; these cells have a more foamy and vacuolated cytoplasm (i.e. containing multiple vacuoles) than type A cells [15] and often resemble foamy histiocytes or sebaceous gland cells. [17] The tumor cells have low to moderate rates of proliferation based on their Ki-67 protein levels. [7] PACB tissues may have localized areas that contain mucin-like secretions within their luminal ducts, [10] localized areas of necrosis (i.e. foci containing dead or dying cells), and/or microcalcifications spotted throughout the apocrine tissue. [11] The stroma (i.e. connective tissue between the sheets, nests, papilla and cords of cells) typically contains non-malignant, infiltrating lymphocytes (see Fig. 3). In an examination of 41 PABC tumors, 33 (80.5%) had <50% of their stroma tissues infiltrated with these cells while 8 (19.5%) had ≥50% of their stroma tissues infiltrated with them. Tumors with ≥50% of their stroma infiltrated with lymphocytes tended to have carcinoma cells that had high rates of proliferation. [11] Metastatic and recurrent PACB tumors have a histopathology similar to their original primary tumors. [14]

Using the Nottingham system which classifies breast cancers into 3 grades based or their progressively more aggressive histopathology and potentially poorer prognoses, studies have found the PACB tumors in: a) 20 individuals were grade 1, 2, and 3 tumors in 3, 11, 6 cases, respectively; [14] b) 41 individuals were grade 1, 2, and 3 tumors in 0, 30, and 11 cases, respectively; [11] and c) 18 individuals, all of whom had HER2/neu tumors, were grade 1, 2, or 3 in 1, 11 and 6 cases, respectively. [10] Using the American Joint Committee on guidelines for classifying breast cancer tumors into 4 stages with progressively poorer prognoses based on increasing tumor size (stages I to III) or nearby chest wall or skin involvement or distant tissue metastases (stage 1V): a) the study of 41 cases of PACB reported 5 had stage I, 24 had stage II, 9 had stage III, and 3 had stage IV disease; [11] b) the study of 20 individuals reported 14 had stage I, 4 had stage II, 2 had stage III, and none had stage IV disease; [14] and c) the study of 18 individuals with triple-negative tumors reported 7 had stage I, 9 had stage II, 2 had stage III, and none had stage IV disease. [10]

Immunohistochemistry

The definition of PACB requires that immunohistochemical analyses find that at least 10% of its cancer cells express androgen receptors but none of these cells express estrogen or progesterone receptors. HER2/neu (which is located on the surface membrane of cells) is not upregulated, and therefore scored as HER/neu-negative, in 43%, [7] 58.5%, [11] 70.8%, [10] or 90% [14] of PACB cases. HER/neu-negative PACB is one of the triple-negative breast cancers (TNBCs). TNBCs are a group of estrogen receptor-, androgen receptor-, and HER2/neu-negative tumors that account for 10%-15% of all breast cancers and are particularly aggressive cancers that generally have a poorer prognosis than other breast cancer subtypes. [18] HER2/neu is in the epidermal growth factor receptor family. Another member of this family, epidermal growth factor receptor (also termed Her1) is sometimes (e.g. 6% of cases) overexpressed in PACB, particularly in cases that are HER2/neu-negative. [7]

All PACB cases have tumor cells which express the alpha-methylacyl-CoA racemase protein [19] and nearly all of these cases have tumor cells which express the GATA3 protein. [5] [20] The identification of these two proteins in tumor cells has helped support the diagnosis of PACB. [5] Prolactin-induced protein, a product of the PIP gene, has been reported to be expressed by the tumor cells in up to 75% of PABC tumors in earlier studies [1] and 100% (26 of 26 cases) in a more recent study. [19] Since this protein is commonly expressed in many other types of breast carcinoma, its identification has not useful for diagnosing PACB. [19] Finally, a study of 14 individuals with PACB found that 7 had infiltrating lymphocytes that expressed PD-L1 (i.e. programmed death-ligand 1), a protein that when upregulated may allow cancer cells to evade the host immune system. [11] However, another study found that only 2 of 17 cases had PACB infiltrating lymphocytes that expressed PD-L1 protein. [10]

Gene abnormalities

A study of 14 individuals with PACB reported that their tumor cells commonly had abnormalities in genes that code for proteins in three intercellular signaling pathways known to be responsible for regulating cell growth, proliferation, and/or survival. These pathways were the PI3K/AKT/mTOR, cyclin-dependent kinase, and MAPK/ERK pathways. All of these pathways, when dysregulated, are implicated in promoting the development and/or progression of various types of breast cancers. [11] The most commonly identified gene mutations in the carcinoma cells of 18 individuals with PACB were the PIK3CA gene in 12, PTEN tumor suppressor gene in 6, and TP53 tumor suppressor gene in 5 individuals. Less commonly, these cells had mutations in the BRAF, HRAS, KRAS , proto-oncogenes, or MAP3K1 gene all of which are in MAPK/ERK pathways, the CK4, CK6A, CK6B, or CK6C gene in the cyclin-dependent pathways, and the FGF2 gene (i.e. the basic fibroblast growth factor gene). [4] One or more of these dysregulated pathways and mutated genes, many studies suggest, contribute to the development and/or progression of PACB tumors. [1] [9] [11] [19] [21] [22]

Diagnosis

The diagnosis of PACB is based on its histopathology [23] which should show an invasive tumor consisting of >90% apocrine morphology (see histopathology section) with apocrine-like cancinoma cells that do not express estrogen or progesterone receptors but in at least 10% of these cells do express the androgen receptor. [12] [14] The uptake of PAS diastase stain by the tumor's carcinoma cells' cytoplasmic granules can aid in making the diagnosis. [13] PACB is distinguished from three other very rare breast cancers with which it shares a similar morphology. Oncocytic carcinoma of the breast [5] [24] differs from PABC in being composed of tumor cells dominated by excessive numbers of mitochondria. [16] Granular cell tumor of the breast [25] and breast tumors consisting predominantly of cells with foamy cytoplasm resembling histiocytes (i.e. histiocytoid variant of invasive lobular carcinoma [26] also termed hystiocytoid breast carcinoma [27] ) differ from PACB in that their cancer cells do not express GATA3 or alpha-methylacyl-CoA racemase but do express the S100 protein. [5]

Treatment and prognosis

PACB tumors have commonly been treated with regimens similar to those used to treat various non-apocrine breast carcinomas. The standard treatment for PACB has been tumor removal using either breast-conserving surgery or mastectomy with removal of any nearby axillary lymph nodes suspected of containing metastases. [13] Because of the predicted severity of their tumors presentation and histopathology, almost all patients are further treated with a) radiation therapy to the involved areas, [10] administered as adjuvant therapy after surgery or as neoadjuvant therapy before surgery; [23] b) a chemotherapy regimen, [10] administered after or before surgery; [23] and/or c) in HER2/neu-positive cases, trastuzumab, which is a monoclonal antibody that binds to HER2/neu protein thereby suppressing its pro-cancerous actions. [11] In a study of 41 cases, the 5 year overall survival rate was 100% for individuals with HER2/neu-positive PACB tumors and ~72% for individuals with HER2/neu-negative PACB tumors. Since 9 of the 17 HER2/neu-positive individuals in this study received a HER2/Neu-targeting drug, trastuzumab (brand name Herceptin), these results, although not statistically significant, suggest that individuals with HER2/neu-positive PACB may be benefited by adding a HER2/neu-targeted drug to their treatment regimen. Paradoxically, the 5 year overall survival rate in this study for individuals with slower proliferating tumors (Ki-67 ≤20%) was lower, 67%, than that for individuals with faster growing tumors (Ki-67 >20%), ~94%; again, this difference was not statistically significant. [11] In a study of 18 individuals with NER2/neu-negative PACB, 17 were treated with mastectomy and one was treated with breast-conserving surgery; 14 of these individuals were also treated with chemotherapy and 4 with radiation therapy. None of these individuals were treated with a drug targeting HER2/neu. After a median follow-up of 76.5 months, 15 individuals had no disease-related morbidity or mortality while 2 individuals developed distant tissue metastases and one had died. [10] There is little data on the optimal treatment for, or long term (e.g. >10 years) results of, these currently used treatments for PACB. [9] [14]

Many researchers have recommended a) conducting a much larger study to verify the results suggesting that the addition of a HER2/neu inhibitor to standard therapeutic regimens improves the overall survival of individuals with HER2/neu-positive PACB; [11] b) studies to determine if androgen receptor inhibitors (e.g. bicalutamide) [5] or treatments that target the dysregulated PI3K/AKT/mTOR pathway, the cyclin-dependent kinase pathways, and/or the Ras-Raf-MEK-ERK pathway have a role in treating PACB; [11] and c) conducting more comprehensive studies that profile PACB tumors to identify other potential therapeutic targets and regimens for treating this carcinoma. [5] [4]

Other types of apocrine carcinomas

Apocrine ductal carcinoma in situ

Fig 4. Apocrine ductal carcinoma in situ Breast DCIS Apocrine PA.JPG
Fig 4. Apocrine ductal carcinoma in situ

Non-invasive apocrine carcinoma of the breast, i.e. apocrine carcinoma in situ, is classified as a variant of the ductal carcinoma in situ tumors of the breast; it is therefore termed apocrine ductal carcinoma in situ (ADCIS). [9] ADCIS tumors have appreciable areas with apocrine tissue-like histopathology, i.e. areas composed of apocrine cells that have, to varying extents, the abnormal cytoplasmic, nuclear, and nucleolar features found in PACB (see Fig 4). Unlike PACB, the apocrine carcinoma cells in ADCIS have by definition not spread beyond their ducts of origin to invade nearby non-ductal tissue and have not metastasized to local lymph nodes or distant tissues. [4] While there is no consensus on the criteria used for its diagnosis, ADCIS is most often defined as a non-invasive breast tumor consisting of lactiferous ducts that are filled with neoplastic apocrine cells; [4] the cells in these tumors, similar to those in PACB, are estrogen receptor-negative, progesterone-receptor negative, and, in at least 10% of these cells, androgen receptor-positive. [9] Some studies have classified ADCIS as low, intermediate, or high nuclear grade based on how closely the nuclei of their tumor's apocrine cells resemble the nuclei of normal breast cells. In general, high nuclear grade tumor cells have more abnormal nuclei and indicate that this tumor is more aggressive than a lower grade tumor. Low- and intermediate-grade ADCIS tumors may be misdiagnosed as non-cancerous lesions (e.g. as atypical apocrine metaplasia or atypical apocrine hyperplasia) because of their more benign microscopic appearance. [4] ADCIS tumors often have architectural patterns consisting of cribriform (riddled with small holes), micropapillary (thin finger-like growths) and/or solid growth (i.e. do not contain cysts or liquid areas), [4] sites with necrosis, and/or sites with microcalcifications; while these microscopic findings are more common in high nuclear grade ADCIS, their presence supports the diagnosis of ADCIS in low and intermediate tumors. [9] Some authors have proposed that in situ ductal tumors with apocrine histopathology should be larger than 0.2 centimeters in order to be diagnosed as ADCIS. [4] [9]

A study of 22 females aged 31 to 84 years (average age: 59 years) diagnosed with ADCIS reported that on presentation, 9 were asymptomatic (tumors detected by mammography), 11 were palpable breast masses with 2 of them associated with a nipple discharge and 2 of them diagnosed in females with Paget's disease of the breast (Two cases had no information on their presentations). None of the 22 individuals had invasive or metastatic disease including 9 who had armpit lymph node removals to investigate for metastases. The tumors ranged from 0.7 to 6 cm (mean: 2.3 cm) in size. On microscopic examination, the tumors had a microscopic histopathology similar to PACB tumors with 10 cases showing a cribriform pattern and 5 showing a micropapillary pattern. The tumors were estrogen receptor-negative, progesterone receptor-negative, and androgen receptor-positive in all cases except for one case with borderline estrogen receptor-positivity and another case with progesterone receptor-positivity. Ten of these individuals had HER2/neu-positive tumors. In the 17 individuals for whom this information was available, mastectomy, modified mastectomy, and simple mastectomy were performed in 8, 7, and 1 case, respectively; 5 also received adjuvant (i.e. post-surgery) radiotherapy. All of the treated individuals were alive without evidence of disease or recurrences from 9 to 194 months (average observation time: 37 months) after surgery. [28] In a more recent study of 28 females (mean age:56 years) presenting with ADCIS: 28 had estrogen receptor-negative and androgen receptor-positive tumors; 25 (89.3% ) had progesterone-negative tumors; 9 (32.1%) had HER2/neu-positive tumors; 27 had tumors cells that expressed the α-methylacyl-CoA racemase protein; and 27 had tumor cells that expressed the prolactin-inducible protein. These results were virtually identical to those found in PACB tumor cells except for the 3 individuals with progesterone receptor-positive ADCIS tumor cells. During the follow-up period (15–55 months, mean: 32.0 months), all of the females were alive. [29] The potential for ADCIS tumors to progress to a more malignant form is unclear but must be considered as a possibility. [30]

Apocrine-like invasive carcinoma

Apocrine-like invasive carcinoma (ALIC), also termed apocrine-like carcinoma or invasive carcinoma with apocrine differentiation, has been defined as an invasive carcinoma that consists of a PACB-like microscopic histopathology in 10% to 90% of its tumor tissues [1] or a PACB-like microscopic histopathology in >90% of its tumor tissues but, unlike PACB, has tumor cells which are estrogen receptor-positive and/or progesterone receptor-positive. [7] Reports on individuals with ALIC have been rare. A study published in 2013 compared 25 individuals presenting with ALIC to 44 with PACB. There were no significant differences between the two groups in age, tumor size, or lymph node metastases although patients with PACB had higher (50%), but statistically insignificant, rates of lymph note metastases than patients with ALIC (36%). These metastases were found in 1 to 10 lymph nodes of the patients. PABC tumors did have statistically significant increased aggressive histopathology and higher grades compared to ALIC tumors. Tumor grading was based on the Nottingham system, also termed the Elston and Ellis modification, which scores the tumor cells' tubule formation, nuclear pleomorphism, and mitotic counts (see Nottingham system for grading breast cancer tumors). A higher grade tumor is more likely to have a poorer prognosis than a lower grade tumor. The patients were treated with mastectomy or more conservative breast surgery in all cases and, where deemed appropriate, with intraoperative electron radiation therapy or post-surgery radiotherapy in 35 and 24 individuals with PABC and ALIC, respectively. Possibly due to their tumors' greater rate of metastases, more aggressive histopathology, and higher grade, more than half of the individuals with PABC were also treated with chemotherapy and/or hormone therapy; individuals with ALIC did not receive these additional treatments. Relapse rates including those occurring at or near the original tumor site, spread to distant tissues, and/or occurrences in the opposite breast were 7.3% and 3.3% for individuals with PABC and ALIC, respectively. (Patients with either PACB or ALIC had an increased risk of developing a cancer in the opposite breast compared to a control group of patients with Invasive carcinoma of no special type). Ten year disease-free survival rates were about 50% and 70% and ten year overall survival rates (i.e. surviving patients minus patients who died from any cause) were about 80% and 90% for individuals with PABC and ALIC, respectively. The difference in disease-free survival rates (but not the overall survival rates) between individuals with PABC and ALIC was significant. [31] Further studies with larger numbers of patients are required to further define the features of ALIC and accurately compare its long-term prognosis to PACB as well as other breast cancer tumors. [1]

Related Research Articles

<span class="mw-page-title-main">Breast cancer</span> Cancer that originates in mammary glands

Breast cancer is a cancer that develops from breast tissue. Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, milk rejection, fluid coming from the nipple, a newly inverted nipple, or a red or scaly patch of skin. In those with distant spread of the disease, there may be bone pain, swollen lymph nodes, shortness of breath, or yellow skin.

<span class="mw-page-title-main">Metastasis</span> Spread of a disease inside a body

Metastasis is a pathogenic agent's spread from an initial or primary site to a different or secondary site within the host's body; the term is typically used when referring to metastasis by a cancerous tumor. The newly pathological sites, then, are metastases (mets). It is generally distinguished from cancer invasion, which is the direct extension and penetration by cancer cells into neighboring tissues.

<span class="mw-page-title-main">Apocrine</span> Classification of secretion of exocrine glands

Apocrine is a term used to classify the mode of secretion of exocrine glands. In apocrine secretion, secretory cells accumulate material at their apical ends, often forming blebs or "snouts", and this material then buds off from the cells, forming extracellular vesicles. The secretory cells therefore lose part of their cytoplasm in the process of secretion.

This is a list of terms related to oncology. The original source for this list was the US National Cancer Institute's public domain Dictionary of Cancer Terms.

<span class="mw-page-title-main">Lumpectomy</span> Limited surgical removal of breast tissue

Lumpectomy is a surgical removal of a discrete portion or "lump" of breast tissue, usually in the treatment of a malignant tumor or breast cancer. It is considered a viable breast conservation therapy, as the amount of tissue removed is limited compared to a full-breast mastectomy, and thus may have physical and emotional advantages over more disfiguring treatment. Sometimes a lumpectomy may be used to either confirm or rule out that cancer has actually been detected. A lumpectomy is usually recommended to patients whose cancer has been detected early and who do not have enlarged tumors. Although a lumpectomy is used to allow for most of the breast to remain intact, the procedure may result in adverse affects that can include sensitivity and result in scar tissue, pain, and possible disfiguration of the breast if the lump taken out is significant. According to National Comprehensive Cancer Network guidelines, lumpectomy may be performed for ductal carcinoma in situ (DCIS), invasive ductal carcinoma, or other conditions.

<span class="mw-page-title-main">Invasive carcinoma of no special type</span> Medical condition

Invasive carcinoma of no special type, invasive breast carcinoma of no special type (IBC-NST), invasive ductal carcinoma (IDC), infiltrating ductal carcinoma (IDC) or invasive ductal carcinoma, not otherwise specified (NOS) is a disease. For international audiences this article will use "invasive carcinoma NST" because it is the preferred term of the World Health Organization (WHO).

Ductal carcinoma <i>in situ</i> Pre-cancerous breast lesion

Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive cancerous lesion of the breast. DCIS is classified as Stage 0. It rarely produces symptoms or a breast lump that can be felt, typically being detected through screening mammography. It has been diagnosed in a significant percentage of men.

Breast cancer management takes different approaches depending on physical and biological characteristics of the disease, as well as the age, over-all health and personal preferences of the patient. Treatment types can be classified into local therapy and systemic treatment. Local therapy is most efficacious in early stage breast cancer, while systemic therapy is generally justified in advanced and metastatic disease, or in diseases with specific phenotypes.

<span class="mw-page-title-main">Medullary breast carcinoma</span> Rare type of breast cancer

Medullary breast carcinoma is a rare type of breast cancer that is characterized as a relatively circumscribed tumor with pushing, rather than infiltrating, margins. It is histologically characterized as poorly differentiated cells with abundant cytoplasm and pleomorphic high grade vesicular nuclei. It involves lymphocytic infiltration in and around the tumor and can appear to be brown in appearance with necrosis and hemorrhage. Prognosis is measured through staging but can often be treated successfully and has a better prognosis than other infiltrating breast carcinomas.

Lobular carcinoma <i>in situ</i> Medical condition

Lobular carcinoma in situ (LCIS) is an incidental microscopic finding with characteristic cellular morphology and multifocal tissue patterns. The condition is a laboratory diagnosis and refers to unusual cells in the lobules of the breast. The lobules and acini of the terminal duct-lobular unit (TDLU), the basic functional unit of the breast, may become distorted and undergo expansion due to the abnormal proliferation of cells comprising the structure. These changes represent a spectrum of atypical epithelial lesions that are broadly referred to as lobular neoplasia (LN).

Breast cancer classification divides breast cancer into categories according to different schemes criteria and serving a different purpose. The major categories are the histopathological type, the grade of the tumor, the stage of the tumor, and the expression of proteins and genes. As knowledge of cancer cell biology develops these classifications are updated.

<span class="mw-page-title-main">Male breast cancer</span> Medical condition

Male breast cancer (MBC) is a cancer in males that originates in their breasts. Males account for less than 1% of new breast cancers with about 20,000 new cases being diagnosed worldwide every year. Its incidence rates in males vs. females are, respectively, 0.4 and 66.7 per 100,000 person-years. The worldwide incidences of male as well as female breast cancers have been increasing over the last few decades. Currently, one of every 800 men are estimated to develop this cancer during their lifetimes.

<span class="mw-page-title-main">Poroma</span>

Poromas are rare, benign, cutaneous adnexal tumors. Cutaneous adnexal tumors are a group of skin tumors consisting of tissues that have differentiated towards one or more of the four primary adnexal structures found in normal skin: hair follicles, sebaceous sweat glands, apocrine sweat glands, and eccrine sweat glands. Poromas are eccrine or apocrine sweat gland tumors derived from the cells in the terminal portion of these glands' ducts. This part of the sweat gland duct is termed the acrosyringium and had led to grouping poromas in the acrospiroma class of skin tumors. Here, poromas are regarded as distinct sweat gland tumors that differ from other sweat gland tumors by their characteristic clinical presentations, microscopic histopathology, and the genetic mutations that their neoplastic cells have recently been found to carry.

Porocarcinoma (PCA) is a rare form of skin cancer that develops in eccrine sweat glands, i.e. the body's widely distributed major type of sweat glands, as opposed to the apocrine sweat glands which are located primarily in the armpits and perineal area. This cancer typically develops in individuals as a single cutaneous tumor in the intraepidermal spiral part of these sweat glands' ducts at or near to where they open on the skin's surface. PCA tumors are classified as one form of the cutaneous adnexal tumors; in a study of 2,205 cases, PCA was the most common (11.8%) form of these tumors.

<span class="mw-page-title-main">Spiradenoma</span> Medical condition

Spiradenomas (SA) are rare, benign cutaneous adnexal tumors that may progress to become their malignant counterparts, i.e. spiradenocarcinomas (SAC). Cutaneous adnexal tumors are a group of skin tumors consisting of tissues that have differentiated towards one of the four primary adnexal structures found in normal skin: hair follicles, sebaceous sweat glands, apocrine sweat glands, and eccrine sweat glands. SA and SAC tumors were regarded as eccrine gland tumors and termed eccrine spiradenomas and eccrine spiradenocarcinomas, respectively. However, more recent studies have found them to be hair follicle tumors and commonly term them spiradenomas and spiradenocarcinomas, respectively. Further confusing the situation, SA-like and SAC-like tumors are also 1) manifestations of the inherited disorder, CYLD cutaneous syndrome (CCS), and 2) have repeatedly been confused with an entirely different tumor, adenoid cystic carcinomas of the salivary gland. Here, SA and SAC are strictly defined as sporadic hair follicle tumors that do not include the hereditary CCS spiradenomas and heridtary spiradenocarcinoms of CCS or the adenoid cystic carcinomas.

<span class="mw-page-title-main">Salivary duct carcinoma</span> Medical condition

Salivary duct carcinoma (SDC) is a rare type of aggressive cancer that arises from the salivary glands. It is predominantly seen in men and, generally, has a poor prognosis. Other high grade carcinomas can mimic SDC. About 40-60% of SDC arise in pleomorphic adenomas. Most, if not all, SDCs express androgen receptor by immunohistochemistry. Therapeutically relevant genetic alterations include ERBB2/Her2 amplification, PIK3CA and/or HRAS mutations.

Papillomatosis of the breast (PB) is a rare, benign, epitheliosis-like lesion, i.e. an overgrowth of the cells lining the ducts of glands that resembles a papilla or nipple-like nodule/tumor. PB tumors develop in the apocrine glands of the breast. PB is also termed juvenile papillomatosis because of its frequent occurrence in younger women and Swiss cheese disease because of its microscopic appearance. Rarely, PB has also been diagnosed in very young, adolescent, and adult males.

Mammary secretory carcinoma (MSC), also termed secretory carcinoma of the breast, is a rare form of the breast cancers. MSC usually affects women but in a significant percentage of cases also occurs in men and children. Indeed, McDvitt and Stewart first described MSC in 1966 and termed it juvenile breast carcinoma because an increased number of cases were at that time diagnosed in juvenile females. MSC is the most common form of breast cancer in children, representing 80% of childhood breast cancers, although it accounts for less than 0.15% of all breast cancers.

Papillary carcinomas of the breast (PCB), also termed malignant papillary carcinomas of the breast, are rare forms of the breast cancers. The World Health Organization (2019) classified papillary neoplasms of the breast into 5 types: intraductal papilloma, papillary ductal carcinoma in situ (PDCIS), encapsulated papillary carcinoma (EPC), solid-papillary carcinoma (SPC), and invasive papillary carcinoma (IPC). The latter four carcinomas are considered here; intraductal papilloma is a benign neoplasm. The World Health Organization regarded solid papillary carcinoma as having two subtypes: in situ and invasive SPC.

<span class="mw-page-title-main">Invasive cribriform carcinoma of the breast</span> Medical condition

Invasive cribriform carcinoma of the breast (ICCB), also termed invasive cribriform carcinoma, is a rare type of breast cancer that accounts for 0.3% to 0.6% of all carcinomas in the breast. It originates in a lactiferous duct as opposed to the lobules that form the alveoli in the breasts' mammary glands. ICCB was first described by Dixon and colleagues in 1983 as a tumor that on microscopic histopathological inspection had a cribriform pattern, i.e. a tissue pattern consisting of numerous "Swiss cheese"-like open spaces and/or sieve-like small holes. The latest edition (2019) of the World Health Organization (2019) termed these lesions invasive cribriform carcinomas indicating that by definition they must have a component that invades out of their ducts of origin into adjacent tissues. In situ ductal cancers that have a cribriform histopathology are regarded as belonging to the group of ductal carcinoma in situ tumors.

References

  1. 1 2 3 4 5 6 D'Arcy C, Quinn CM (January 2019). "Apocrine lesions of the breast: part 2 of a two-part review. Invasive apocrine carcinoma, the molecular apocrine signature and utility of immunohistochemistry in the diagnosis of apocrine lesions of the breast". Journal of Clinical Pathology. 72 (1): 7–11. doi:10.1136/jclinpath-2018-205485. PMID   30425121. S2CID   53307540.
  2. ↑ Javed A, Lteif A (February 2013). "Development of the human breast". Seminars in Plastic Surgery. 27 (1): 5–12. doi:10.1055/s-0033-1343989. PMC   3706056 . PMID   24872732.
  3. ↑ Bartlett TE, Jia P, Chandna S, Roy S (December 2021). "Inference of tissue relative proportions of the breast epithelial cell types luminal progenitor, basal, and luminal mature". Scientific Reports. 11 (1): 23702. Bibcode:2021NatSR..1123702B. doi:10.1038/s41598-021-03161-7. PMC   8655091 . PMID   34880407.
  4. 1 2 3 4 5 6 7 8 D'Arcy C, Quinn C (January 2019). "Apocrine lesions of the breast: part 1 of a two-part review: benign, atypical and in situ apocrine proliferations of the breast". Journal of Clinical Pathology. 72 (1): 1–6. doi:10.1136/jclinpath-2018-205484. PMID   30409840. S2CID   53237988.
  5. 1 2 3 4 5 6 7 Vranic S, Gatalica Z (June 2022). "An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast". Clinical Breast Cancer. 22 (4): e576–e585. doi: 10.1016/j.clbc.2021.12.009 . hdl: 10576/25634 . PMID   35027319. S2CID   245534362.
  6. ↑ d'Amore ES, Terrier-Lacombe MJ, Travagli JP, Friedman S, Contesso G (September 1988). "Invasive apocrine carcinoma of the breast: a long term follow-up study of 34 cases". Breast Cancer Research and Treatment. 12 (1): 37–44. doi:10.1007/BF01805738. PMID   2848603. S2CID   2219443.
  7. 1 2 3 4 5 Vranic S, Tawfik O, Palazzo J, Bilalovic N, Eyzaguirre E, Lee LM, Adegboyega P, Hagenkord J, Gatalica Z (May 2010). "EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast". Modern Pathology. 23 (5): 644–53. doi: 10.1038/modpathol.2010.50 . PMID   20208479. S2CID   205199873.
  8. ↑ Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, Lazar AJ, Morris EA, Sahin A, Salgado R, Sapino A, Sasano H, Schnitt S, Sotiriou C, van Diest P, White VA, Lokuhetty D, Cree IA (August 2020). "The 2019 World Health Organization classification of tumours of the breast". Histopathology. 77 (2): 181–185. doi: 10.1111/his.14091 . hdl: 11343/252349 . PMID   32056259. S2CID   211111446.
  9. 1 2 3 4 5 6 7 8 9 Quinn CM, D'Arcy C, Wells C (January 2022). "Apocrine lesions of the breast". Virchows Archiv. 480 (1): 177–189. doi:10.1007/s00428-021-03185-4. PMC   8983539 . PMID   34537861.
  10. 1 2 3 4 5 6 7 8 9 10 11 12 Sun X, Zuo K, Yao Q, Zhou S, Shui R, Xu X, Bi R, Yu B, Cheng Y, Tu X, Lu H, Yang W (December 2020). "Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas". Modern Pathology. 33 (12): 2473–2482. doi: 10.1038/s41379-020-0589-x . PMID   32504034. S2CID   219318408.
  11. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Xiao X, Jin S, Zhangyang G, Xiao S, Na F, Yue J (June 2022). "Tumor-infiltrating lymphocytes status, programmed death-ligand 1 expression, and clinicopathological features of 41 cases of pure apocrine carcinoma of the breast: a retrospective study based on clinical pathological analysis and different immune statuses". Gland Surgery. 11 (6): 1037–1046. doi: 10.21037/gs-22-248 . PMC   9253190 . PMID   35800740.
  12. 1 2 3 4 Choe AI, Maley OR, Kim PM (April 2022). "Case of the Season: Invasive Apocrine Carcinoma of the Breast". Seminars in Roentgenology. 57 (2): 121–125. doi:10.1053/j.ro.2021.12.002. PMID   35523524. S2CID   245486389.
  13. 1 2 3 4 Barron M, Asaad A, Idaewor P, Rasheed N, Saad Abdalla Al-Zawi A (October 2021). "Breast Apocrine Carcinoma Detected Incidentally as Axillary Lymphadenopathy in a CT Scan". Cureus. 13 (10): e18523. doi: 10.7759/cureus.18523 . PMC   8569647 . PMID   34754678.
  14. 1 2 3 4 5 6 7 8 9 Mills AM, E Gottlieb C, M Wendroth S, M Brenin C, Atkins KA (August 2016). "Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-Positive Subset of Triple-Negative Breast Cancers". The American Journal of Surgical Pathology. 40 (8): 1109–16. doi:10.1097/PAS.0000000000000671. PMID   27259012. S2CID   44841712.
  15. 1 2 3 Vranic S, Schmitt F, Sapino A, Costa JL, Reddy S, Castro M, Gatalica Z (November 2013). "Apocrine carcinoma of the breast: a comprehensive review". Histology and Histopathology. 28 (11): 1393–409. doi:10.14670/HH-28.1393. PMID   23771415.
  16. 1 2 O'Malley FP, Bane AL (January 2004). "The spectrum of apocrine lesions of the breast". Advances in Anatomic Pathology. 11 (1): 1–9. doi:10.1097/00125480-200401000-00001. PMID   14676636. S2CID   34257743.
  17. ↑ Sekal M, Znati K, Harmouch T, Riffi AA (2014). "Apocrine carcinoma of the male breast: a case report of an exceptional tumor". The Pan African Medical Journal. 19: 294. doi:10.11604/pamj.2014.19.294.2973. PMC   4393957 . PMID   25883722.
  18. ↑ Won KA, Spruck C (December 2020). "Triple‑negative breast cancer therapy: Current and future perspectives (Review)". International Journal of Oncology. 57 (6): 1245–1261. doi:10.3892/ijo.2020.5135. PMC   7646583 . PMID   33174058.
  19. 1 2 3 4 Srivastava P, Wang T, Clark BZ, Yu J, Fine JL, Villatoro TM, Carter GJ, Brufsky AM, Gorantla VC, Huggins-Puhalla SL, Emens LA, Basili T, da Silva EM, Reis-Filho JS, Bhargava R (April 2022). "Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers". npj Breast Cancer. 8 (1): 51. doi:10.1038/s41523-022-00415-z. PMC   9021249 . PMID   35444182.
  20. ↑ Wendroth SM, Mentrikoski MJ, Wick MR (February 2015). "GATA3 expression in morphologic subtypes of breast carcinoma: a comparison with gross cystic disease fluid protein 15 and mammaglobin". Annals of Diagnostic Pathology. 19 (1): 6–9. doi:10.1016/j.anndiagpath.2014.12.001. PMID   25544392.
  21. ↑ Vranic S, Feldman R, Gatalica Z (February 2017). "Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers". Bosnian Journal of Basic Medical Sciences. 17 (1): 9–11. doi:10.17305/bjbms.2016.1811. PMC   5341783 . PMID   28027454.
  22. ↑ Vranic S, Marchiò C, Castellano I, Botta C, Scalzo MS, Bender RP, Payan-Gomez C, di Cantogno LV, Gugliotta P, Tondat F, di Celle PF, Mariani S, Gatalica Z, Sapino A (September 2015). "Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast". Human Pathology. 46 (9): 1350–9. doi:10.1016/j.humpath.2015.05.017. PMID   26208846.
  23. 1 2 3 Zhang N, Zhang H, Chen T, Yang Q (April 2017). "Dose invasive apocrine adenocarcinoma has worse prognosis than invasive ductal carcinoma of breast: evidence from SEER database". Oncotarget. 8 (15): 24579–24592. doi:10.18632/oncotarget.15597. PMC   5421871 . PMID   28445946.
  24. ↑ Itagaki H, Yamamoto T, Hiroi A, Kawanishi K, Noguchi E, Ohchi T, Kamio T, Kameoka S, Oda H, Nagashima Y (March 2017). "Synchronous and bilateral oncocytic carcinoma of the breast: A case report and review of the literature". Oncology Letters. 13 (3): 1714–1718. doi:10.3892/ol.2017.5610. PMC   5403532 . PMID   28454314.
  25. ↑ Meani F, Di Lascio S, Wandschneider W, Montagna G, Vitale V, Zehbe S, Harder Y, Parvex SL, Spina P, Canonica C, Generali D, Pagani O (December 2019). "Granular cell tumor of the breast: a multidisciplinary challenge". Critical Reviews in Oncology/Hematology. 144: 102828. doi:10.1016/j.critrevonc.2019.102828. PMID   31710955. S2CID   207934384.
  26. ↑ Aldulaijan FA, Alsahwan AG, Alsulaiman MH, Mashhour MM, Alwabari A (December 2021). "Histiocytoid variant of invasive lobular breast carcinoma. A case report and literature review". Annals of Medicine and Surgery (2012). 72: 103091. doi:10.1016/j.amsu.2021.103091. PMC   8626566 . PMID   34868577.
  27. ↑ Tan PH, Harada O, Thike AA, Tse GM (August 2011). "Histiocytoid breast carcinoma: an enigmatic lobular entity". Journal of Clinical Pathology. 64 (8): 654–9. doi: 10.1136/jcp.2011.088930 . PMID   21398688. S2CID   19633717.
  28. ↑ Vougiouklakis T, Belovarac BJ, Lytle A, Chiriboga L, Ozerdem U (September 2020). "The diagnostic utility of EZH2 H-score and Ki-67 index in non-invasive breast apocrine lesions". Pathology, Research and Practice. 216 (9): 153041. doi:10.1016/j.prp.2020.153041. PMID   32825929. S2CID   219919047.
  29. ↑ Nakamura H, Kukita Y, Kunimasa K, Kittaka N, Kusama H, Nakayama T, Tamaki Y, Sugiura R, Yasuda H, Hashimoto M, Yamamoto T, Imamura F, Nakatsuka SI (October 2021). "α-Methylacyl-CoA racemase: a useful immunohistochemical marker of breast carcinoma with apocrine differentiation". Human Pathology. 116: 39–48. doi:10.1016/j.humpath.2021.07.005. PMID   34314764.
  30. ↑ Leal C, Henrique R, Monteiro P, Lopes C, Bento MJ, De Sousa CP, Lopes P, Olson S, Silva MD, Page DL (May 2001). "Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers". Human Pathology. 32 (5): 487–93. doi:10.1053/hupa.2001.24327. PMID   11381366.
  31. ↑ Dellapasqua S, Maisonneuve P, Viale G, Pruneri G, Mazzarol G, Ghisini R, Mazza M, Iorfida M, Rotmensz N, Veronesi P, Luini A, Goldhirsch A, Colleoni M (April 2013). "Immunohistochemically defined subtypes and outcome of apocrine breast cancer". Clinical Breast Cancer. 13 (2): 95–102. doi:10.1016/j.clbc.2012.11.004. PMID   23245877.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.